| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/31/2003 | US20030143559 A modified estrogen receptor alpha ligand binding domain containing an amino acid modification in region 1, at region 2, or atleast one amino acid modifiation in both of regions, and these domain interacts with a nonendogenous ligand |
| 07/31/2003 | US20030143312 Baking adjuvant |
| 07/31/2003 | US20030143304 Human and animal nutrition and dietary supplementation |
| 07/31/2003 | US20030143280 For therapy of dry eye |
| 07/31/2003 | US20030143279 Method for preparing microparticles having a selected polymer molecular weight |
| 07/31/2003 | US20030143278 Vaginal delivery of drugs |
| 07/31/2003 | US20030143275 Cosmetic and/or dermatological composition containing at least one oxidation-sensitive hydrophilic active principle and at least one N-vinylimidazole polymer or copolymer |
| 07/31/2003 | US20030143272 Pharmaceutical tablet and process for making thereof |
| 07/31/2003 | US20030143271 For therapy and prophylaxis of cyclooxygenase-2 mediated disorder and for providing cardioprotection |
| 07/31/2003 | US20030143270 Extended release composition containing Tramadol |
| 07/31/2003 | US20030143269 Tamper-resistant oral opioid agonist formulations |
| 07/31/2003 | US20030143265 Administering riboflavin or derivatives |
| 07/31/2003 | US20030143260 Administering to the cow salt of ester of methionine, an ester of methionine amide, and an ester of the hydroxy analogue of methionine |
| 07/31/2003 | US20030143259 Topical treatment or prevention of ocular infections |
| 07/31/2003 | US20030143257 For controlled release of the drug |
| 07/31/2003 | US20030143252 Inorganic/organic complexes for reducing skin irritation |
| 07/31/2003 | US20030143251 Skin preparations for external use |
| 07/31/2003 | US20030143246 Ganoderma lucidum spores for treatment of autoimmune diseases |
| 07/31/2003 | US20030143243 Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| 07/31/2003 | US20030143232 Incubating survivin and p34cdc2-cyclin B1 kinase complex in presence of an agent; determining whether agent modulates phosphorylation of survivin by p34cdc2-cyclin B1 kinase complex, identifying an agent which modulates phosphorylation |
| 07/31/2003 | US20030143231 Assaying the ability of the compound to modulate 57749 nucleic acid expression or 57749 polypeptide activity, thereby identifying a compound capable of treating a pain disorder |
| 07/31/2003 | US20030143230 Combination of an IL-1/18 inhibitor with a TNF inhibitor for the treatment of inflammation |
| 07/31/2003 | US20030143225 Administering a dose of anti-tissue factor antibody and a suboptimal dose of at least one additional anticoagulant selected from the group consisting of heparin, low molecular weight heparin, pentasaccharide thrombin inhibotrs |
| 07/31/2003 | US20030143223 Modulating the activity of one or more elements in the complement/lipid pathway |
| 07/31/2003 | US20030143204 Making the inhibitor consisting of an RNA function inhibiting sequence that is specific to expressible nucleic acid sequence in mammal; inserting the inhibitor into a vessel in the mammal; delivering function inhibiting sequence to a cell |
| 07/31/2003 | US20030143199 Administering to a mammal subject to interferon treatment a compound which is an antagonist of IL-4 or IL-13 signal transduction pathway in an amount effective to enhance efficacy |
| 07/31/2003 | US20030143197 Administering to the animal omega interferon (IFN) at a dosage and activity for the disease state treated sufficient to induce a therapeutic response in the animal |
| 07/31/2003 | US20030143195 Use of histamine as a drug delivery enhancing compound for use in transmucosal or transdermal delivery |
| 07/31/2003 | US20030143189 Therapy for topical diseases |
| 07/31/2003 | US20030143185 Polymer conjugates of protein kinase C inhibitors |
| 07/31/2003 | US20030143184 Shelf life of longer than three years in a sterilized container, stability of longer than three days in infusion fluid, has minimal side effects and shows improved bioavailability |
| 07/31/2003 | US20030143183 Combined use of a GLP-1 compound and another drug for treating dyslipidemia |
| 07/31/2003 | US20030143181 Use of cationic compounds |
| 07/31/2003 | US20030143173 Formulations and methods for straightening hair |
| 07/31/2003 | US20030143166 Aqueous dispersion of water-insoluble organic UV filter substances |
| 07/31/2003 | US20030143165 Regularly applying a topical formulation to the skin of patient, formulation containing a pharmaceutically effective amount of a non- steroidal anti-inflammatory drug |
| 07/31/2003 | US20030143163 For therapy of respiratory disorders; aerosol formulations of use for the administration of medicaments by inhalation |
| 07/31/2003 | US20030143162 Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics |
| 07/31/2003 | US20030143161 Medicine, carrier for medicine, method of producing medicine, and method of tumor treatment |
| 07/31/2003 | US20030140920 Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma |
| 07/31/2003 | DE29824938U1 Pharmaceutical preparation comprising clodronate |
| 07/31/2003 | DE20305898U1 Pharmaceutical compositions include vitamins and optionally trace elements to enhance the therapeutic effect and/or reduce the side effects of drugs |
| 07/31/2003 | CA2840490A1 Polyalkylene glycol with moiety for conjugating biologically active compounds |
| 07/31/2003 | CA2753899A1 Polyalkylene glycol with moiety for conjugating biologically active compounds |
| 07/31/2003 | CA2514088A1 Use of cholinesterase antagonists to treat insulin resistance |
| 07/31/2003 | CA2514081A1 Use of phosphodiesterase antagonists to treat insulin resistance |
| 07/31/2003 | CA2511238A1 Pteridine derivatives, method for the production thereof, and use thereof |
| 07/31/2003 | CA2486588A1 Method for the production of resveratrol in cell cultures |
| 07/31/2003 | CA2476984A1 Lactoferrin as an agent for enhancing action of an opioid |
| 07/31/2003 | CA2476565A1 Methods and compositions for reducing the development of drug tolerance and/or physical dependence |
| 07/31/2003 | CA2474623A1 Peptides and nucleic acids of the cathelicidin family, derived from fish, and uses thereof |
| 07/31/2003 | CA2474337A1 Compounds useful as a3 adenosine receptor agonists |
| 07/31/2003 | CA2474292A1 Sustained release pharmaceutical composition |
| 07/31/2003 | CA2474269A1 Nutraceuticals for the treatment, protection and restoration of connective tissues |
| 07/31/2003 | CA2474201A1 Statins (hmg-coa reductase inhibitors) as a novel type of immunomodulator, immunsuppressor and anti-inflammatory agent |
| 07/31/2003 | CA2474077A1 Methods for treatment of multiple sclerosis with statins |
| 07/31/2003 | CA2473944A1 Methods and compositions for rna interference |
| 07/31/2003 | CA2473927A1 Methods and compositions for treating polycystic ovary syndrome |
| 07/31/2003 | CA2473924A1 Systems and methods for photodynamic therapy |
| 07/31/2003 | CA2473906A1 Cooperative oligonucleotides |
| 07/31/2003 | CA2473884A1 Method of treatment of a patient requiring analgesia |
| 07/31/2003 | CA2473829A1 Use of tgf-.beta. antagonists to treat or to prevent chronic transplant rejection |
| 07/31/2003 | CA2473799A1 Triterpene quaternary salts as biologically active surfactants |
| 07/31/2003 | CA2473796A1 Substituted quinazolin-4-ylamine analogues |
| 07/31/2003 | CA2473763A1 Compounds for modulating cell proliferation |
| 07/31/2003 | CA2473748A1 Novel targeted compositions for diagnostic and therapeutic use |
| 07/31/2003 | CA2473740A1 Methods of treating conditions associated with an edg receptor |
| 07/31/2003 | CA2473721A1 Use of benzothiazepines having activity as inhibitors of ileal bile acid transport for reducing cholesterololemia |
| 07/31/2003 | CA2473717A1 Dna dosage forms |
| 07/31/2003 | CA2473698A1 Anti-inflammatory formulations |
| 07/31/2003 | CA2473697A1 Compositions for pulmonary administration |
| 07/31/2003 | CA2473679A1 Dna dosage forms |
| 07/31/2003 | CA2473545A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
| 07/31/2003 | CA2473536A1 Pharmaceutical composition and method for treating disorders of the central nervous system |
| 07/31/2003 | CA2473510A1 Pyrimidine derivatives as rho-kinase inhibitors |
| 07/31/2003 | CA2473508A1 Pyrimidinone viral polymerase inhibitors |
| 07/31/2003 | CA2473490A1 Peptide-carrying bodies for immune response |
| 07/31/2003 | CA2473489A1 Use of inhibitors of soluble epoxide hydrolase to inhibit vascular smooth muscle cell proliferation |
| 07/31/2003 | CA2473474A1 Alteration of rab38 function to modulate mammalian pigmentation |
| 07/31/2003 | CA2473420A1 Tricyclic 2-pyrimidone compounds useful as hiv reverse transcriptase inhibitors |
| 07/31/2003 | CA2473395A1 Phospholipid bodies and use thereof in medical treatment |
| 07/31/2003 | CA2473392A1 5-ht3 receptor antagonists and methods of use |
| 07/31/2003 | CA2473386A1 Method |
| 07/31/2003 | CA2473254A1 Combination therapy for the treatment of bacterial infections |
| 07/31/2003 | CA2473059A1 Apparatus and process for preparing crystalline particles |
| 07/31/2003 | CA2473047A1 Phosphinic pseudo-peptide derivatives for selective inhibition of the active c-terminal site of angiotensin converting enzyme (i) (ace) |
| 07/31/2003 | CA2473040A1 A weight management system for obese animals |
| 07/31/2003 | CA2473036A1 Melanocortin receptor agonists |
| 07/31/2003 | CA2473032A1 Novel peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 07/31/2003 | CA2472835A1 Fused bicyclic pyrimidine derivatives |
| 07/31/2003 | CA2472682A1 Treating stress response with chemokine receptor ccr5 modulators |
| 07/31/2003 | CA2472680A1 Selective s1p1/edg1 receptor agonists |
| 07/31/2003 | CA2472578A1 Anti-cancer combination and use thereof |
| 07/31/2003 | CA2472564A1 Aqueous antiseptic composition comprising an antimicrobial agent, a high concentration of a hydroxycarboxylic acid buffer, and a cationic film-forming polymer |
| 07/31/2003 | CA2472367A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
| 07/31/2003 | CA2472240A1 Tibolone in the treatment of complaints associated with the administration of drugs which prevent the synthesis of endogenous estrogen |
| 07/31/2003 | CA2472239A1 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases |
| 07/31/2003 | CA2472238A1 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors |
| 07/31/2003 | CA2471989A1 2-aminothiazole allosteric enhancers of a1 adenosine receptors |
| 07/31/2003 | CA2471749A1 Biocidal compounds and their preparation |